These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22175142)

  • 61. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.
    de Koning HD; Schalkwijk J; van der Meer JW; Simon A
    J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363
    [No Abstract]   [Full Text] [Related]  

  • 62. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?
    Nigrovic PA
    Arthritis Rheumatol; 2014 Jun; 66(6):1405-13. PubMed ID: 24623686
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease.
    Priori R; Ceccarelli F; Barone F; Iagnocco A; Valesini G
    Clin Exp Rheumatol; 2008; 26(5):933-7. PubMed ID: 19032833
    [No Abstract]   [Full Text] [Related]  

  • 64. The 'alphabet' of rheumatoid arthritis treatment.
    Capriotti T
    Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
    [No Abstract]   [Full Text] [Related]  

  • 65. [New treatments for rheumatoid arthritis].
    Girault V; Flipo RM
    Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
    [No Abstract]   [Full Text] [Related]  

  • 66. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.
    Hallegua DS; Weisman MH
    Ann Rheum Dis; 2002 Nov; 61(11):960-7. PubMed ID: 12379516
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
    Cavalli G; Dinarello CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 69. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract]   [Full Text] [Related]  

  • 70. Early detection of sensorineural hearing loss in Muckle-Wells-syndrome.
    Kuemmerle-Deschner JB; Koitschev A; Tyrrell PN; Plontke SK; Deschner N; Hansmann S; Ummenhofer K; Lohse P; Koitschev C; Benseler SM
    Pediatr Rheumatol Online J; 2015 Nov; 13(1):43. PubMed ID: 26531310
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Treatment of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):101-4. PubMed ID: 10355058
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder.
    Zufferey P; So A
    Ann Rheum Dis; 2013 Mar; 72(3):465-7. PubMed ID: 23144448
    [No Abstract]   [Full Text] [Related]  

  • 74. [Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra].
    Klein AK; Horneff G
    Klin Padiatr; 2010 Jul; 222(4):266-8. PubMed ID: 20135584
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature.
    Ruscitti P; Cipriani P; Cantarini L; Liakouli V; Vitale A; Carubbi F; Berardicurti O; Galeazzi M; Valenti M; Giacomelli R
    J Med Case Rep; 2015 Jun; 9():123. PubMed ID: 26033326
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Autoinflammation in 2010: expanding clinical spectrum and broadening therapeutic horizons.
    Ombrello MJ; Kastner DL
    Nat Rev Rheumatol; 2011 Feb; 7(2):82-4. PubMed ID: 21289614
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Blocking interleukin-1 in rheumatic diseases.
    Goldbach-Mansky R
    Ann N Y Acad Sci; 2009 Dec; 1182():111-23. PubMed ID: 20074280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Case of anakinra as a steroid-sparing agent for gout inflammation.
    Gratton SB; Scalapino KJ; Fye KH
    Arthritis Rheum; 2009 Sep; 61(9):1268-70. PubMed ID: 19714614
    [No Abstract]   [Full Text] [Related]  

  • 79. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
    Botsios C; Sfriso P; Ostuni PA; Todesco S; Punzi L
    Rheumatology (Oxford); 2007 Jun; 46(6):1042-3. PubMed ID: 17449489
    [No Abstract]   [Full Text] [Related]  

  • 80. Switch from anakinra to canakinumab in a severe case of CINCA syndrome.
    Rigante D; Verrecchia E; Falsini B; Manna R
    Int J Rheum Dis; 2016 Dec; 19(12):1354-1356. PubMed ID: 26585548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.